27 Sep 2017 --- Wacker has announced the results of a human clinical study demonstrating that their hydroxytyrosol HTEssence is capable of significantly reducing low-density lipoprotein (LDL) cholesterol. At SupplySide West 2017 (September 27-29, Las Vegas), the company is exhibiting its “nature-identical” hydroxytyrosol HTEssence.